--- title: "Starcoin Group Signs Strategic Biotech Cooperation MOU With Huamei Haibo" type: "News" locale: "en" url: "https://longbridge.com/en/news/280552119.md" description: "Starcoin Group Limited has signed a memorandum of understanding with Huamei Haibo Biotechnology for strategic cooperation in equity investment, asset restructuring, and Web3.0 healthcare. The partnership aims to integrate Huamei Haibo’s cell-preparation systems and technologies, enhancing Starcoin's R&D and commercialization efforts in biotech. This collaboration is expected to create new revenue streams and strengthen Starcoin's position in the healthcare sector. The latest analyst rating for Innovative Pharmaceutical Biotech (HK:0399) is a Sell with a price target of HK$0.15." datetime: "2026-03-25T22:39:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280552119.md) - [en](https://longbridge.com/en/news/280552119.md) - [zh-HK](https://longbridge.com/zh-HK/news/280552119.md) --- # Starcoin Group Signs Strategic Biotech Cooperation MOU With Huamei Haibo ### Claim 30% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The latest announcement is out from Innovative Pharmaceutical Biotech ( (HK:0399) ). Starcoin Group Limited has signed a memorandum of understanding with Chongqing-based Huamei Haibo Biotechnology to pursue strategic cooperation spanning equity investment, asset restructuring, Web3.0 healthcare, joint business development, financing, and a potential U.S. de-SPAC transaction. The collaboration framework also covers integration and commercialization of Huamei Haibo’s core cell-preparation systems, supplier and supply-chain platforms, exclusive cell-technology rights, equipment management, consumables distribution, and hospital-side data and financial technology systems. By partnering with Huamei Haibo, a specialist in AI-driven cell manufacturing equipment and medical services with exclusive licenses for key cell standards and patents, Starcoin aims to secure exclusive access to proprietary cell technologies and technical services. The board expects this to strengthen the group’s R&D base, complement its oral insulin programme, and open pathways for commercialization and industrial deployment of advanced cell technologies, with the goal of building new revenue streams and reinforcing its positioning in biotech and healthcare. The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.15 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page. **More about Innovative Pharmaceutical Biotech** Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, operates in the biotechnology and healthcare sector with a focus on pharmaceutical and related life-science technologies. The group is developing an oral insulin programme and is seeking to expand its presence across broader biotech and healthcare markets through strategic partnerships and advanced technology integration. **Average Trading Volume:** 42,676,800 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$340.7M For a thorough assessment of 0399 stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [HAO.US](https://longbridge.com/en/quote/HAO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [SANA.US](https://longbridge.com/en/quote/SANA.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md) - [Berkshire Hathaway exits UnitedHealth stake with 45% gain](https://longbridge.com/en/news/286676948.md) - [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md) - [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)